A Quick Look at Today's Ratings for Black Diamond Therapeutics(BDTX.US), With a Forecast Between $11 to $18
On Sep 24, major Wall Street analysts update their ratings for $Black Diamond Therapeutics(BDTX.US)$, with price targets ranging from $11 to $18.TD Cowen analyst Marc Frahm maintains with a buy
Black Diamond Theraptcs Price Target Maintained With a $11.00/Share by HC Wainwright & Co.
Express News | Black Diamond Therapeutics Inc : Stifel Raises Target Price to $18 From $15
Buy Rating on Black Diamond Therapeutics: Promising Phase 2 Results for BDTX-1535 in NSCLC Treatment
Piper Sandler Maintains Overweight on Black Diamond Therapeutic, Raises Price Target to $15
US Equity Futures Gain as Investors Search for Fresh Catalysts After Fed Rate Cut
Sector Update: Health Care
Market-Moving News for September 23rd
Black Diamond Therapeutics Shares Jump on Positive Data for Cancer Treatment
Top Premarket Gainers
Black Diamond Reports Phase 2 Results for BDTX-1535 in Lung Cancer, Targets FDA Approval Path
Express News | Black Diamond Therapeutics Inc - Initial Results of Bdtx-1535 in First-Line Nsclc Patients With Non-Classical Egfr Mutations Expected Q1 2025
Black Diamond Therapeutics Announces Initial Phase 2 Data Demonstrating Robust Anti-tumor Activity of BDTX-1535 in Patients With Recurrent EGFRm NSCLC Who Present With a Broad Spectrum of Classical, Non-classical, and C797S Resistance Mutations
Black Diamond Therapeutics to Host Webcast Presentation of Initial Phase 2 BDTX-1535 Data in Patients With Recurrent EGFRm NSCLC
Buy Rating Affirmed for Black Diamond Therapeutics Amid Promising NSCLC Treatment Advances
Black Diamond Therapeutics Presents Real-World Treatment Practices and Patient Outcomes in Newly Diagnosed NSCLC Patients With Non-Classical Mutations at the European Society for Medical Oncology (ESMO) Congress 2024
Daily futures tracking | Chip stocks have rebounded over the past few days, Nvidia and Broadcom single trading are active; gold and silver spot has soared, and related ETF bullish options have earned nearly 20 times overnight
Are bears sniping at Intel? The bearish ratio rose to 72%, and put trading volume increased dramatically; Broadcom rose by 3.97% to lead the rise in star technology stocks, and earned 6 times the profit from a single call due in October.
Stifel Maintains Black Diamond Therapeutics(BDTX.US) With Buy Rating, Maintains Target Price $15
Stifel analyst Bradley Canino maintains $Black Diamond Therapeutics(BDTX.US)$ with a buy rating, and maintains the target price at $15.According to TipRanks data, the analyst has a success rate of 41.
Wedbush Maintains Black Diamond Therapeutics(BDTX.US) With Buy Rating, Maintains Target Price $16
Wedbush analyst Robert Driscoll maintains $Black Diamond Therapeutics(BDTX.US)$ with a buy rating, and maintains the target price at $16.According to TipRanks data, the analyst has a success rate of 4
Piper Sandler Maintains Black Diamond Therapeutics(BDTX.US) With Buy Rating, Maintains Target Price $12
Piper Sandler analyst Joseph Catanzaro maintains $Black Diamond Therapeutics(BDTX.US)$ with a buy rating, and maintains the target price at $12.According to TipRanks data, the analyst has a success